Data gathered: January 22
AI Stock Analysis - Regeneron (REGN)
Analysis generated December 6, 2024. Powered by Chat GPT.
Regeneron Pharmaceuticals is a biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for the treatment of serious medical conditions. With a strong pipeline and a reputation for innovation, Regeneron has established itself as a leader in the biotech industry. However, recent data presents a mixed picture, necessitating a deeper analysis of its financials, stock performance, and market sentiment.
Stock Alerts - Regeneron (REGN)
 |
Regeneron | January 22 News Alert: Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – REGN |
|
Regeneron | January 11 Web Traffic is down by 35.7% over the last month. |
|
Regeneron | January 10 Price is down by -5.2% in the last 24h. |
|
Regeneron | December 23 Job postings are down by 21.9% in the last couple of days. |
Alternative Data for Regeneron
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 340 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 229,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 33 | Sign up | Sign up | Sign up |
| Patents | 1,391 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 186 | Sign up | Sign up | Sign up |
| Facebook Followers | 18,004 | Sign up | Sign up | Sign up |
| Instagram Followers | 13,792 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 16,060 | Sign up | Sign up | Sign up |
| Twitter Followers | 33,086 | Sign up | Sign up | Sign up |
| Twitter Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | 3 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 58 | Sign up | Sign up | Sign up |
| Lobbying Cost | $133,000 | Sign up | Sign up | Sign up |
| Business Outlook | 78 | Sign up | Sign up | Sign up |
| Linkedin Employees | 15,582 | Sign up | Sign up | Sign up |
About Regeneron
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
| Price | $683.72 |
| Target Price | Sign up |
| Volume | 339,880 |
| Market Cap | $74.9B |
| Year Range | $681.58 - $1201.76 |
| Dividend Yield | 0% |
| PE Ratio | 16.86 |
| Analyst Rating | 73% buy |
| Earnings Date | February 4 '25 |
| Industry | Biotechnology |
In the news
 |
REGENERON PHARMACEUTICALS SECURITIES FRAUD NOTICE: Berger Montague Informs Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of Securities Fraud LawsuitJanuary 21 - Investing.com |
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – REGNJanuary 21 - GlobeNewswire |
|
|
Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGNJanuary 21 - Investing.com |
INVESTOR REMINDER: Berger Montague Notifies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of a Class Action Lawsuit and DeadlineJanuary 21 - GlobeNewswire |
|
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGNJanuary 21 - Finnhub |
|
 |
Aaron Wealth Advisors LLC Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)January 21 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 3.72B | 714M | 3.01B | 1.34B | 0 | 12.460 |
| Q2 '24 | 3.55B | 759M | 2.79B | 1.43B | 1.21B | 11.560 |
| Q1 '24 | 3.13B | 689M | 2.44B | 722M | 873M | 9.550 |
| Q4 '23 | 3.42B | 947M | 2.47B | 1.16B | 1.26B | 11.860 |
| Q3 '23 | 3.34B | 641M | 2.7B | 1.01B | 1.11B | 11.590 |
Insider Transactions View All
| McCourt Marion filed to sell 12,931 shares at $844.6. November 5 '24 |
| RYAN ARTHUR F filed to sell 17,678 shares at $1042.3. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,582 shares at $1059.3. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,586 shares at $1056.7. October 3 '24 |
| RYAN ARTHUR F filed to sell 17,592 shares at $1053.5. October 3 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Jonathan Jackson |
Dec 13, 24 | Sell | $15K - $50K |
| Jonathan Jackson |
Dec 13, 24 | Sell | $1K - $15K |
| Josh Gottheimer |
Dec 6, 24 | Sell | $1K - $15K |
Read more about Regeneron (REGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Regeneron?
The Market Cap of Regeneron is $74.9B.
What is Regeneron's PE Ratio?
As of today, Regeneron's PE (Price to Earnings) ratio is 16.86.
When does Regeneron report earnings?
Regeneron will report its next earnings on February 4 '25.
What is the current stock price of Regeneron?
Currently, the price of one share of Regeneron stock is $683.72.
How can I analyze the REGN stock price chart for investment decisions?
The REGN stock price chart above provides a comprehensive visual representation of Regeneron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Regeneron shares. Our platform offers an up-to-date REGN stock price chart, along with technical data analysis and alternative data insights.
Does REGN offer dividends to its shareholders?
As of our latest update, Regeneron (REGN) does not offer dividends to its shareholders. Investors interested in Regeneron should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Regeneron?
Some of the similar stocks of Regeneron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.